Neurocrine Biosciences, Inc. · NASDAQ:NBIX
Neurocrine Biosciences — Investor Presentation (November 2008)
47 slides from Neurocrine Biosciences's investor presentation, Nov 20, 2008
Slide 1: A Pipeline of Website Presentation
A Pipeline of Website Presentation 11/20/08
Slide 2: Forward-looking risk statement
This presentation includes early and late stage clinical data and projections based thereon that involve a number of risks and uncertainties. These risks include the specific risk that the clinical development of the products discussed will not successfully proceed to later stage clinical trials or
Slide 3: Pipeline
Pipeline Products Indication Preclinical Phase 1 Phase 2 Phase 3 Elagolix Endometriosis Elagolix Benign Prostatic Hyperplasia CRF1 Antagonist Anxiety/Depression (561679) CRF1 Antagonist A i Irritable Bowel Syndrome (IBS) (876008) CRF1 Antagonist (586529) Anxiety/Depression CRF2 Peptide Agonist (Uroc
Slide 4: GnRH Program
GnRH Program Orally Available, Nonpeptide Antagonists A Pipeline of Website Presentation 11/20/08
Slide 5: Nonpeptide GnRH Antagonists First in Class Opportunity
Nonpeptide GnRH Antagonists First in Class Opportunity Administration • Ease of Use • Oral dosing • Flexible dosing Women’s Men’s Health GnRH Antagonist Health Efficacy Efficac • No flare effect • Quick onset of action A Pipeline of Website Presentation 11/20/08
Slide 6: GnRH is the Central Regulator of Reproductive Endocrine System
GnRH is the Central Regulator of Reproductive Endocrine System in Men and Women Clinical Applications of Hypothalamic-Pituitary-Gonadal Axis GnRH Analogues Hypothalamus Prostate Cliniical Practice e ART Endometriosis Cancer Optic GnRH Chiasma Precocious Uterine Breast Pituitary Puberty Fibroids Canc
Slide 7: U.S. Endometriosis Market
U.S. Endometriosis Market Large, clinically significant patient base Many women of child …and symptoms are primarily bearing age have perceived as moderate or endometriosis… severe by those diagnosed… 8 7 23% 6MM 6 5 Milllions 4 3 2 1 77% 0 N = 62,481 Prevalence in Mild Moderate/Severe generall popu
Slide 8: Endometriosis Treatment Options
Endometriosis Treatment Options Option Issues Wait for menopause It could be a while… NSAIDS (e.g. advil) Insufficient pain relief Oral Contraceptives (OCPs) Insufficient pain relief May help get pregnant, but Laparascopic ablation typically recurs Hysterectomy/remove H ste ectom / emo e oovaries a
Slide 9: Elagolix Clinical Trials as of September 2008
Elagolix Clinical Trials as of September 2008 Total Subjects on Study Description Study Number Subjects 56418 Ph I SD / MD, female NBI-56418-0301 55 45 Ph I Site absorption, male NBI-56418-0401 6 6 Ph I SD male SD, NBI 56418 0402 NBI-56418-0402 8 8 Ph I Formulation, relative PK, male NBI-56418-0404
Slide 10: Key Efficacy Endpoints 3-Month Studies
Key Efficacy Endpoints 3-Month 501 & 504 Studies: Week 12 Placebo Elagolix Study Study Study Study Study Study 0501 0504 0501 0504 0501 0504 75 mg 50 mg 150 mg 100 mg qd bid qd bid Endpoint Statistic (n=28) (n=20) (n=25) (n=21) (n=23) (n=24) CFB CPSSS Mean -3.7 -4.5 -3.8 -4.4 -5.2 -5.9 Baseline~8 CF
Slide 11: Safety Assessment 12 Weeks of Treatment
Safety Assessment 501 & 504 Studies 12 Weeks of Treatment Placebo Elagolix Study Study Study Study Study Study 0501 0504 0501 0504 0501 0504 75 mg 50 mg 150 mg 100 mg qd bid qd bid (n=28) (n=20) (n=25) (n=21) (n=23) (n=24) Discontinuation due to AE 4% 0% 20% 9% 4% 8% Overall AE Incidence 86% 85% 84%
Slide 12: NBI-56418-0603 Top-line Results After 6-Month Treatment
NBI 56418 0603 NBI-56418-0603 Top-line Results After 6-Month Treatment September 2008 A Pipeline of Website Presentation 11/20/08
Slide 13: Target Product Profile Elagolix - Endometriosis
Target Product Profile Elagolix - Endometriosis Characteristic Ideal Profile Indication The management of pain associated with endometriosis Duration 6 months with multiple re‐treatments • CPSSS: mean ↓ ≥ 5 • VAS: mean ↓ ≥ 20 Efficacy • Rapid onset < 1 month • Improvement in EHP‐5 (QoL) • No active
Slide 14: Petal Study Design
Petal Study Design A Pipeline of Website Presentation 11/20/08
Slide 15: Recruitment and Baseline Characteristics
Recruitment and Baseline Characteristics Recruitment Inquiries to Call Center Referred to Site Total number 8022 3393 Characteristic Elagolix 150 mg qd Elagolix 75 mg bid DMPA SC n=84 n=84 n=84 mean (SD) mean (SD) mean (SD) Age 32.4 (7.5) 31.4 (6.1) 31.6 (0.4) CPSSS total 9.2 (2.0) 9.0 (2.0) 9.2 (2.
Slide 16: Primary Endpoint – Bone Mineral Density
Primary Endpoint – Bone Mineral Density Pre-specified endpoint : DXA % change from baseline to Month 6 Lower bound of 95% CI to show no greater loss than -2.2% A Pipeline of Website Presentation 11/20/08
Slide 17: Study Successful at Primary Endpoint
Study Successful at Primary Endpoint LS Mean and 95% Confidence Interval A Pipeline of Website Presentation 11/20/08
Slide 18: BMD % Change From Baseline at Month 6
BMD % Change From Baseline at Month 6 Elagolix 150 mg qd Elagolix 75 mg bid DMPA-SC Femur n=56 56 n=63 63 n=51 51 LS Mean % -0.4732 -0.9940 -1.2891 95% CI % -0.9645,, 0.0181 -1.4572,, -0.5308 -1.8039,, -0.7743 Elagolix 150 mg qd Elagolix 75 mg bid DMPA-SC Spine n=55 n=62 n=50 LS M Mean % -0.1135 0 1
Slide 19: Elagolix Effects on Bone Compare Favorably
Elagolix Effects on Bone Compare Favorably Women 20-45 yyears of age g Duration of Change in Treatment or Treatment/Condition Reference S i Spine BMD Ob Observation i (months) Leuprolide depot Agarwal, 1998 ((GnRH agonist) g ) for -4 to -10% 6 (review of multiple studies) endometriosis -1.2% 6 Crosi
Slide 20: Elagolix is Safe and Well Tolerated
Elagolix is Safe and Well Tolerated Outcome Elagolix 150 mg qd Elagolix 75 mg bid DMPA-SC Completed 6-month Rx 67% 73% 61% Deaths 0 0 0 Discontinued due to SAE 0 0 2.4% Reported any AE 79% 81% 79% Discontinued due to AE 5% 7% 16% Adverse Event Elagolix 150 mg qd Elagolix 75 mg bid DMPA SC DMPA-SC >1
Slide 21: Hot Flashes
Hot Flashes Comparable rate of hot flashes during 1 month of screening i and d 6 monthsth off treatment t t t Elagolix 150 mg Elagolix 75 mg Statistic DMPA SC qd bid During Screening n=84 n=84 n=84 Mean #/day (SD) 0.248 (0.453) 0.321 (1.106) 0.295 (0.787) Median #/day 0.000 0.000 0.000 During Treatm
Slide 22: Reduction in Vaginal Bleeding
Reduction in Vaginal Bleeding Mean (SD)% of Days With Any Bleeding 60 Screening — Reduction in vaginal g Treatment bleeding reflects 50 pharmacological effect of 40 treatments — DMPA is associated with 30 amenorrhea and 20 persistent spotting — Elagolix is associated with 10 decrease in menses or 0
Slide 23: Reasons for Discontinuation During Treatment
Reasons for Discontinuation During Treatment PETAL Study Preliminary Data Prior to Unblinding Reason for Elagolix 150 mg qd Elagolix 75 mg bid DMPA-SC Total Discontinuation n=84 n=84 n=84 n=252 n (%) n (%) n (%) n (%) Adverse event 4 (4.8) 6 (7.1) 13 (15.5) 23 (9.1) Protocol deviation 2 (2.4) 0 (0)
Slide 24: Secondary Endpoints
Secondaryy Endpoints p Significant Si ifi t IImprovementt iin Endometriosis Symptoms CPSSS and VAS A Pipeline of Website Presentation 11/20/08
Slide 25: Clinically Meaningful and Statistically Significant Change from Baseline
Clinically Meaningful and Statistically Significant Change from Baseline Secondary endpoints p<0.0001 LS Mean* Score Reduction at Month 6 Mean Score Elagolix Elagolix DMPA-SC Efficacy Assessment at Baseline 150 mg qd 75 mg bid 104 mg n=252 n=54 n=63 n=48 CPSSS Total 9.1 -5.5 -5.2 -5.3 D Dysmenorrhea
Slide 26: Significant Improvement in Total CPSSS
Significant Improvement in Total CPSSS Mean±SEM Change From Baseline) (M A Pipeline of Website Presentation 11/20/08
Slide 27: Significant Improvement in Monthly Peak VAS
Significant Improvement in Monthly Peak VAS A Pipeline of Website Presentation 11/20/08
Slide 28: Petal Study Successful
Petal Study Successful Pain reduction without bone loss ¾ Primary endpoint met – Lower bound of 95%CI did not exceed -2.2% change from baseline for either spine or femur bone mineral density – Data support selection of once daily dosing in 702 and 703 trials ¾ Secondary endpoints met – Significant r
Slide 29: Elagolix Achieves Estradiol Suppression into Target Range
Elagolix Achieves Estradiol Suppression into Target Range Median di Estradiol di l at Week 24 (pg/ ) (pg/mL) Elagolix 150 mg qd Elagolix 75 mg bid n=49 n=56 45.3 29.3 ¾ Hormone Data – Individual patient-level data remains blinded – Median values above reflect preliminary per protocol data set (i.e.,
Slide 30: Additional Data Analyses
Additional Data Analyses ¾ Additional analyses are contingent upon full unblinding of individual patient data and completion of quality control processes – Individual adverse events – Clinical lab values ¾ Pharmacometrics and PK/PD Modeling • Elagolix exposure, estradiol, BMD • Elagolix exposure, ex
Slide 31: Elagolix - Endometriosis Target Product Profile
T a r g e t P r o d u c t P r o f i l e Elagolix g - Endometriosis Characteristic Ideal Profile Indication 9The management of pain associated with endometriosis Duration 96 months with multiple re‐treatments 9CPSSS: mean ↓ ≥ 5 9VAS: mean ↓ ≥ 20 Efficacy 9Rapid onset < 1 month 9Improvement in EHP‐5 (
Slide 32: Clinical Development 2008-09
Clinical Development 2008-09 Elagolix Study Phase Output Timing 0702 Assess placebo run-in, revised Dose confirmation in PhIIb endpoints and DXA assessed at endometriosis d t i i (150mg (150 qd d + 250 F ll Enrolled Fully E ll d higher exposure; mg qd) • topline data (1H09) 0703 As with 0702 plus ac
Slide 33: Multiple Markets - Multiple Compounds
Multiple Markets - Multiple Compounds Women’s Health Men’s Health Gynecology Gynecology Oncology Urology • Endometriosis •Uterine Fibroids • Breast Cancer • Benign Prostatic • Prostate P t t Cancer C H Hypertrophy t h (BPH) First Second Third Elagolix “Phase 2b” Primary Indications Back-Up p “Develo
Slide 34: Elagolix Intellectual Property
Elagolix Intellectual Property 5 Issued U.S. Patents covering: – elagolix composition of matter – pharmaceutical composition – methods of using g elagolix g Last composition of matter patent expires 2024 (not including patent term extension) Corresponding Foreign Applications pending or issued (expi
Slide 35: CRF Receptor Antagonists
CRF Receptor Antagonists A Pipeline of Website Presentation 11/20/08
Slide 36: CRF Antagonists: Current Status of NBI / GSK Compounds
CRF Antagonists Current Status of NBI / GSK Compounds 2006 2007 2008 2009 Phase I Phase II Compound 876008 Phase I POC IBS Ongoing Compound 561679 Phase I Phase II Depression ep ess o Novel chemotype and Studies PoC pharmacologic profile Start mid 2008 Multi-dose study complete Phase I Depression De
Slide 37: Urocortin 2 for Congestive Heart Failure
Urocortin 2 for Urocortin 2 Congestive Congestive Heart Failure ((CHF)) Heart Failure ((CHF)) A Pipeline of Website Presentation 11/20/08
Slide 38: Preclinical Research Provides Insights into Urocortin 2 Action
Preclinical Research Provides Insights into oUUrocortin oco 2 Action c o ¾ Provides acute and sustained afterload reduction due to vasodilatory action and reduction of left ventricle size ¾ Provides an improvement in myocardial relaxation and improves diastolic filling ¾ Provides enhanced myocardial
Slide 39: Impact on Peripheral Resistance
Impact on Peripheral Resistance 80 erial Pressure 60 Mean Arterial Blood Pressure: Dose-proportional decrease in mean m Hg) 40 arterial p pressure (mm Mean Arte 20 0 Predose 1 hr Infusion 4 hr Postdose Placebo Single-blinded, placebo 25 μg UCN2 controlled, dose-escalation 1800 study; 1 hr dosing wit
Slide 40: Improved Cardiac Output and Less Work
Improved Cardiac Output and Less Work 8 Cardiac Output: Cardiac Output (LL / min) Dose-proportional improvement of 6 Caridac Output p in stable CHF 4 patients (up to 50% increase) 2 0 Predose 1 hr Infusion 4 hr Placebo Single-blinded, placebo Postdose 25 μg UCN2 controlled, dose-escalation study; 1
Slide 41: Preclinical Overview
Preclinical Overview ¾ Safety Pharmacology (ICH compliant) — CNS Battery — Cardiopulmonary — Cardiovascular ¾ Preclinical Toxicology — Single dose studies –MTD ¾ Genotoxicity (all negative) — AMES — Mouse Lymphoma — Rat Micronucleus A Pipeline of Website Presentation 11/20/08
Slide 42: Urocortin 2 Summary of Results to Date
Urocortin 2 Summary of Results to Date ¾ Urocortin 2 represents a First in Class opportunity for the treatment of acutely y decompensated p heart failure ((ADHF)) – Novel mechanism of action – Multiple physiological actions ¾ Intravenous t a e ous infusion us o of o Urocortin U oco t 2 in stable sta
Slide 43: R&D Capabilities
Urocortin 2 for R&D Congestive Capabilities p Heart Failure ((CHF)) A Pipeline of Website Presentation 11/20/08
Slide 44: Neurocrine Capabilities: R & D
Neurocrine Capabilities: R & D Discovery Research Preclinical Development Advanced Programs Early Novel Discovery Approaches Preclinical Chemical Pharmaceutical DMPK & Safety Development Development Discovery Research Phase III with CRO / Partner Phase I / II Conducted by NBI Clinical Programs For S
Slide 45: Research Technology
Research Technology Real Time Data Integration in Drug Discovery ¾ Automated Drug Discovery Processes – Chemical synthesis, Purification, Analytical, Focused Libraries – SAR of Primary Assays Assays, hERG hERG, CYP Inhibition ¾ Pharmacology Know-how and Insights - SiNERG – Receptor Kinetics / Recept
Slide 46: Research Targets
Research Targets ¾ Drug discovery platform which integrates the fundamental principles perfected in GPCR pharmacology (kinetics, efficacy, and desensitization) to drive novel target drug discovery / SAR process. – Neurology (Pain, Epilepsy, Movement Disorders) – Metabolic disorders (Diabetes) – Psyc
Slide 47: Financial Highlights
Financial Highlights Year to Date Year Ending September 30, 2008 December 31, 2007 Revenues and $ 3.2 million $ 6.2 million other income Operating and other $ 63.0 million $ 213.5 million Expenses Net income (loss) $ (59.8) million $ (207.3) million Cash and short term $ 118 118.2 2 million illi $ 1
Neurocrine Biosciences — Investor Presentation (November 2008) on 6ix